Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead

All three major indexes are eyeing daily, weekly, and monthly wins

Digital Content Manager
Mar 31, 2023 at 11:57 AM
facebook twitter linkedin

The Dow Jones Industrial Average (DJI) is boasting a triple-digit lead this afternoon, as investors unpack this morning's flood of inflation data. Unlike the S&P 500 Index (SPX) and Nasdaq Composite Index (IXIC), the blue-chip benchmark is still eyeing a quarterly loss, though all three remain on track for weekly and monthly wins. The tech sector led much of this month's gains, with a strong performance from chip stocks. The Cboe Volatility Index (VIX) is eyeing a losing quarter, week, and month, as well as its sixth-straight daily loss.

Continue reading for more on today's market, including: 

  • These 2 Trump-linked stocks are moving higher.
  • Analyst downgrades Generac stock on risk reward.
  • Plus, options bulls blast UBS stock; quarterly win boosts YMAB; and biotech stock extends pullback.

MMC Stats 331

Options bulls are blasting UBS Group AG (NYSE:UBS) today, with 52,000 calls across the tape so far today -- 27 times the intraday average volume -- compared to 1,180 puts. The April 35 and 30 calls are the most popular contacts, with positions being opened at both. UBS is up 3.2% at $21.16 at last check, amid news that Sergio Ermotti will return as CEO for the Credit Suisse (CS) takeover. The security is eyeing its first close above the 40-day moving average in over three weeks, and sports a 13.2% year-to-date lead.

UBS 40 Day

Y-mAbs Therapeutics Inc (NASDAQ:YMAB) is one of the best stocks on the Nasdaq today, last seen up 69.6% to trade at $5.58. The company yesterday reported a surprise fourth-quarter profit of 3 cents per share as well as a revenue beat, with shares brushing off Canaccord Genuity's price-target cut to $18 from $20. YMAB is trading at its highest level since October, and has added 9% so far in 2023.

The shares of Annovis Bio Inc(NYSE:ANVS) were last seen at the bottom of the New York Stock Exchange (NYSE), down 20.5% at $15.99. The company today received the interim analysis for sample size re-estimation for its phase 3 clinical trial of its treatment for early Parkinson's disease. The $14.50 region looks poised to contain this pullback, as ANVS continues to cool from this week's rally to its highest level since September. Year-over-year, the equity is up 19.9%.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 


300x250 - Banner 3 - v1